Undisclosed pharmaceutical companies were among the investors in the venture firm's third fund, which will target biopharmaceutical developers.
Covid-19 Therapeutics Accelerator has launched with $125m to find treatments for the pandemic, $25m of which came from Mastercard.
Repsol is among the limited partners that have committed to the venture firm’s $60m first fund, which is expected to make 10 more investments before 2022.
First Pacific-backed accelerator IdeaSpace’s Opportunity Fund will back pre-series A rounds for its portfolio companies.
Fashion conglomerate TSI Holdings has backed a fund of undisclosed size launched by fashion tech-focused venture capital firm Lyra Ventures.
Bristol Myers Squibb and Otsuka Pharmaceutical were among the limited partners for what LSP said is Europe's largest ever life sciences VC fund.
The Spain-based energy utility is set to contribute approximately $23m to the vehicle, which will invest in renewable energy technology developers.
Phoenix Group and Migdal have supplied capital for Arkin Bio-Ventures II, which investment firm Arkin Holdings will use to invest in 10 to 12 drug developers.